GET DAILY SIGNALSMereo BioPharma (MREO): Analyst Targets Suggest +450% Upside Potential
Key Takeaways
- The $1.60 central target is the arithmetic mean of four verified analyst price targets issued after the December 2025 Phase 3 setback.
- At a recent price near $0.29, reaching $1.60 would require a gain of roughly 450%, a very large move.
- The individual targets range widely, from $0.50 (Jefferies) to $3.00 (Needham), reflecting deep disagreement about the path forward.
- The strongest supports are a cash runway into mid-2027, statistically significant bone-mineral-density (BMD) results, and a Phase 3-ready second program.
- The biggest risks are the missed fracture endpoints, regulatory uncertainty, potential dilution, and dependence on partner Ultragenyx.
- You can find more detail on the company's Major News, Today's Price Move, Forecast, and Earnings pages.
Analyst Targets After the Setback
Four post-failure analyst price targets were reviewed. Jefferies downgraded to Hold with a $0.50 target on December 30, 2025; BTIG trimmed its target to $1.00 while keeping a Buy rating; Leerink Partners held Buy with a $2.00 target; and Needham lowered its target to $3.00 on January 13, 2026, while retaining Buy. The average of these four comes to roughly $1.63, which rounds to the $1.60 central target, with a spread from $0.50 to $3.00. Earlier targets were much higher, such as JPMorgan’s $8.00 Overweight from August 2025, but those predate the Phase 3 results and are now considered outdated.
The wide dispersion shows real differences in outlook. Some analysts see the missed primary endpoints as a major blow to commercial prospects, while others highlight the positive BMD secondary data and the FDA’s willingness to consider alternative fracture analyses. I also checked this using Tickeron’s AI Screener to compare the stock’s positioning within the sector.
Current Price and Required Move
With shares trading near $0.29, the gap to $1.60 implies roughly 450% upside. That kind of advance would not stem from routine updates but from a meaningful re-rating, most likely tied to regulatory clarity on setrusumab, a decision on its BLA path, or a productive partnership for alvelestat. Cash stood at about $41 million at the end of 2025, with runway guidance into mid-2027, which lowers near-term liquidity concerns even as the company continues to operate at a loss.
Factors That Could Support Higher Prices
- Cash runway: Guidance through mid-2027 gives time to explore regulatory and partnering avenues.
- BMD secondary endpoint: Both Phase 3 trials delivered statistically significant bone-mineral-density gains, and the FDA has indicated openness to alternative fracture endpoints.
- Alvelestat: A Phase 3-ready program in alpha-1 antitrypsin deficiency-associated lung disease is advancing toward potential partnering.
- Unmet medical need: No broadly approved treatments exist for osteogenesis imperfecta, which could factor into regulatory and partner decisions.
Risks That Could Limit Upside
- Missed primary endpoints: Setrusumab failed its fracture-rate primary goals, the key hurdle for approval.
- Regulatory uncertainty: Talks with the FDA and UK MHRA continue, but no clear approval pathway has been established.
- Financing needs: A clinical-stage firm may require additional capital, which could pressure the ADR price.
- Partner reliance: Ultragenyx leads global development of setrusumab, limiting Mereo’s direct control.
- Analyst divergence: The spread from $0.50 to $3.00 underscores how much remains unresolved.
Technical Picture and Key Levels
The ADRs sit near the bottom of a 52-week range between roughly $0.20 and $2.37. The drop from above $2.00 has created substantial overhead supply. The $0.50 and $1.00 levels stand out as near-term hurdles that would need to be cleared before a move toward $1.60 looks more feasible. The overall trend remains bearish without a clear fundamental catalyst.
What to Watch Going Forward
Analyst targets generally look out about 12 months. Key items include regulatory feedback from the FDA and MHRA on setrusumab, any further data readouts from the Orbit and Cosmic studies, partnering updates for alvelestat, quarterly cash updates, and potential revisions to analyst targets. Earnings releases will matter mainly for cash-burn trends and strategic commentary rather than near-term revenue.
Monitoring with AI Tools
I also checked this using Tickeron’s AI Trend Prediction Engine to gauge how the technical setup compares with historical patterns in similar situations.
AI Daily Buy/Sell Signals
Tickeron’s AI Daily Buy/Sell Signals apply artificial intelligence to track thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on evolving market conditions, technical factors, and AI analysis. For a volatile name like MREO, where clinical and regulatory news can shift sentiment rapidly, the tool helps identify opportunities, track positions, and spot trend changes more efficiently than manual checks alone. Traders often combine these signals with their own research to stay responsive in fast-moving markets.
Final Assessment
Reaching the $1.60 mean target would require a roughly 450% advance from current levels near $0.29—a very large move that cannot be taken for granted. The supporting case rests on the strong BMD secondary endpoint, FDA openness to alternative analyses, a mid-2027 cash runway, and optionality around alvelestat. The counter-case centers on the missed primary fracture endpoints, ongoing regulatory risk, possible dilution, and limited control over the setrusumab program. With targets spanning $0.50 to $3.00, analyst views remain sharply divided, and upcoming regulatory and partnering milestones will decide whether any re-rating can begin.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MREO in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 12, 2026
MREO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 29 of 32 cases where MREO's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 62 cases where MREO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MREO as a result. In 80 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for MREO just turned positive on November 09, 2026. Looking at past instances where MREO's MACD turned positive, the stock continued to rise in 32 of 44 cases over the following month. The odds of a continued upward trend are 73%.
Following a +6.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where MREO advanced for three days, in 184 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
MREO moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for MREO crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MREO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for MREO entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.577) is normal, around the industry mean (3.498). P/E Ratio (-1.415) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (102.041) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. MREO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MREO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in therapeutics that aim to improve outcomes for patients with osteogenesis imperfecta, alpha-1 antitrypsin deficiency, hypogonadotropic hypogonadism in obese men, and acute exacerbations of chronic obstructive pulmonary disease
Industry Biotechnology
Advertisement